Joseph Rubino

591 citations

6 papers · 290 indexed · h-index 6

Co-authors: Harold Bays Lawrence A. Leiter Scott Conard Joanne E. Tomassini Steven Bird Andrew M. Tershakovec Mary E. Hanson Robert S. Lowe
Topics: Lipoproteins and Cardiovascular Health (3 papers)Pharmaceutical Economics and Policy (2 papers)Hormonal Regulation and Hypertension (2 papers)
Cited by: Cancer Research Endocrinology, Diabetes and Metabolism Surgery
Journals: The American Journal of Cardiology American Heart Journal Clinical Therapeutics
Partner nations: United States Canada Australia

In The Last Decade

Joseph Rubino

6 papers receiving 284 citations

Peers

Countries citing papers authored by Joseph Rubino

Since Specialization

Citations

This map shows the geographic impact of Joseph Rubino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Rubino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Rubino more than expected).

Fields of papers citing papers by Joseph Rubino

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph Rubino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Rubino. The network helps show where Joseph Rubino may publish in the future.

Co-authorship network of co-authors of Joseph Rubino

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph Rubino. A scholar is included among the top collaborators of Joseph Rubino based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph Rubino. Joseph Rubino is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

#	Work	Indexed citations
1	A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma 2016 ·Pediatric Blood & Cancer ·Peter M. Anderson,Stefan Bielack,Richard Görlick,Keith M. Skubitz,Najat C. Daw,Cynthia E. Herzog,Odd R. Monge,Álvaro Lassaletta,Érica Boldrini,(unknown),Joseph Rubino,Kumudu Pathiraja,Darcy A. Hille,Mark Ayers,Siu‐Long Yao,Michael Nebozhyn,Brian Lu,David Mauro	74
2	Effects of the renin inhibitor MK-8141 (ACT-077825) in patients with hypertension 2010 ·Journal of the American Society of Hypertension ·Charlotte Jones-Burton,Joseph Rubino,Sophie Roy,Yabing Mai,Alan G. Meehan,M Bellet,Peter U. Feig	6
3	Design of the DEFINE trial: Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib 2009 ·American Heart Journal ·Christopher P. Cannon,Hayes M. Dansky,Michael H. Davidson,Antonio M. Gotto,Eliot A. Brinton,A. Lawrence Gould,Michael Stepanavage,(unknown),Sukrut Shah,Joseph Rubino,Patrice H. Gibbons,Anne Hermanowski‐Vosatka,Bruce Binkowitz,Yale Mitchel,Philip J. Barter	65
4	Efficacy and Safety of Ezetimibe Added on to Atorvastatin (20 mg) Versus Uptitration of Atorvastatin (to 40 mg) in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease††Conflicts of interest: Dr. Conard served as a consultant and advisor for Merck & Company and Merck/Schering-Plough. Dr. Bays received research grants from Amylin, San Diego, California, Amgen, Thousand Oaks, California, J&J, Langhorne, Pennsylvania, Aegerion, Bridgewater, New Jersey, Abbott, Chicago, Illinois, Arena Pharmaceuticals, San Diego, California, GlaxoSmithKline (Glaxo), London, UK, Hoffmann LaRoche, Nutley, New Jersey, Merck, Whitehouse Station, New Jersey, MSP, Kenilworth, New Jersey, Metabolex, San Jose, California, Schering-Plough, Kenilworth, New Jersey, Orexigen, San Diego, California, Reliant, Liberty Corner, New Jersey, Sciele, Atlanta, Georgia, Takeda, Osaka, Japan, TAP, Lake Forest, Illinois, and Vivus, Mountain View, California; received speakers' honoraria from Abbott, Daiichi Sankyo, Tokyo, Japan, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; received honoraria from Abbott, AstraZeneca, London, UK (Wilmington, Delaware, US Headquarters), Daiichi Sankyo, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; and served as a consultant and advisor for Abbott, GlaxoSmithKline, Metabolex, San Jose, California, Reliant, Takeda, AstraZeneca, and Essentialis, Carlsbad, California. Dr. Leiter received grants and speakers' honoraria from and served as a consultant and advisor for AstraZeneca, Merck & Company, Merck/Schering-Plough, and Pfizer, New York, New York. Mr. Bird, Mr. Rubino, and Drs. Lowe, Tomassini, and Tershakovec are employees of Merck & Company and may own stock and/or hold stock options in the company. 2008 ·The American Journal of Cardiology ·Scott Conard,Harold Bays,Lawrence A. Leiter,Steven Bird,Joseph Rubino,Robert S. Lowe,Joanne E. Tomassini,Andrew M. Tershakovec	62
5	Efficacy and Safety of Ezetimibe Added on to Atorvastatin (40 mg) Compared With Uptitration of Atorvastatin (to 80 mg) in Hypercholesterolemic Patients at High Risk of Coronary Heart Disease 2008 ·The American Journal of Cardiology ·Lawrence A. Leiter,Harold Bays,Scott Conard,Steven Bird,Joseph Rubino,Mary E. Hanson,Joanne E. Tomassini,Andrew M. Tershakovec	71
6	A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertension 2006 ·Clinical Therapeutics ·Gilbert W. Gleim,Joseph Rubino,Hongyan Zhang,Shahnaz Shahinfar,Beth A. Soffer,Paulette A. Lyle,Thomas Littlejohn,Peter U. Feig	12

About Joseph Rubino

Joseph Rubino is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Economics and Econometrics, having authored 6 papers that have together received 290 indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (3 papers), Pharmaceutical Economics and Policy (2 papers) and Hormonal Regulation and Hypertension (2 papers). The work is most often cited by research in Cancer Research (90 citations), Endocrinology, Diabetes and Metabolism (96 citations) and Surgery (187 citations). Joseph Rubino has collaborated with scholars based in United States, Canada and Australia. Frequent co-authors include Harold Bays, Lawrence A. Leiter, Scott Conard, Joanne E. Tomassini, Steven Bird, Andrew M. Tershakovec, Mary E. Hanson, Robert S. Lowe, Michael H. Davidson and Eliot A. Brinton. Their work appears in journals such as The American Journal of Cardiology, American Heart Journal and Clinical Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact